19 results on '"Cherubini B"'
Search Results
2. Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease
3. Long-term outcome of inactive and low viremic HBeAg negative active carriers: Benign one direction transition towards spontaneous HBsAg clearance
4. Early prediction of sustained virologic response by HCV Core Ag kinetics in chronic hepatitis C patients treated with Peginterferon plus Ribavirin
5. OC-25 Bio-mathematical modelling provides the most accurate selection of HCV-G1 patients for triple-therapy
6. T-06 Early HCV-Core-Ag kinetics predict sustained virologic response in chronic hepatitis C patients treated with standard of care
7. P.04.1 IL28B POLYMORPHISM IN CHRONIC HBV INFECTION: THE CC ALLELE DOES NOT CORRELATE WITH THE PHASE OF THE INFECTION NOR WITH HBSAG CLEARANCE IN IFN TREATED PATIENTS
8. P.03.1 IN-HOUSE ALLELE SPECIFIC PCR METHOD TO STUDY THE KINETICS OF RESISTANT VARIANTS DURING NUCLEOS(T)IDE ANALOGS TREATMENT IN IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS
9. OC-11 IL28B polymorphism in chronic HBV infection: the CC allele does not correlate with the phase of the infection nor with HBsAg clearance in IFN treated patients
10. F-26 In-house allele specific PCR method to study the kinetics of resistant variants during nucleos(t)ide analogs treatment in immunocompetent and immunocompromised patients
11. P.1.98: EPIDEMIOLOGY AND SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA: A SINGLE CENTRE COHORT STUDY
12. OC.09.3: MODELLING HCV DYNAMICS ACCORDING TO IL28B POLYMORPHISM SHOWS DIFFERENT ANTIVIRAL EFFECTS OF PEGIFNS/RIBAVIRIN AND PROVIDES A NEW ACCURATE TOOL FOR TREATMENT MANAGEMENT
13. OC.09.5: PRE-S HBV MUTANTS DO NOT AFFECT HBSAG SERUM LEVELS IN HBEAG NEGATIVE GENOTYPE D CARRIERS, BUT ARE ASSOCIATED WITH LIVER DISEASE STAGE AND OLDER AGE
14. F-15 Pre-S HBV mutants do not affect HBsAG serum levels in HBeAg negative genotype D carriers, but are associated with liver disease stage and older age
15. OC-19 Modelling HCV kinetics by IL28B genotype is a new accurate tool for individual treatment management
16. F.N.37 ACCURATE INDIVIDUALIZATION OF PEG-IFN+RBV TREATMENT DURATION BY HCV INFECTED CELL DECLINE COMPUTED IN THE 1ST MONTH OF THERAPY
17. Modelling infected cell dynamics by week 4 HCV RNA and ALT kinetics to compute treatment duration
18. Liver stiffness, a non-invasive marker of liver disease in the HBV carrier
19. Transient elastography as a new tool to monitor HBV carriers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.